retatrutide dosing trials frequency trial dose: the complete guide to protocols, titration, and results Dosing Schedule for Retatrutide: Trial – New Weight Loss Drug Retatrutide:

Weight regain after discontinuing GLP-1 medications is real and documented the STEP 4 trial showed meaningful regain after stopping semaglutide

Retatrutide has not been approved for clinical, medical, or therapeutic use by Health Canada or any regulatory authority

Several mechanisms may potentially contribute to blood pressure effects, including: weight loss (a well-established factor in blood pressure reduction), possible promotion of natriuresis (sodium excretion by the kidneys), and theoretical improvements in endothelial functionthough many of these mechanisms remain hypothetical rather than definitively proven

Summary: There is no universal medical requirement to gradually wean off GLP-1 receptor agonists, as they do not typically cause physical dependence or withdrawal symptoms requiring dose tapering

Heres a closer look at the timeline